The Development Process of an Economic Evaluation Guideline for Lebanon

Caroline Daccache (1,2), Rita Karam (1,3), Silvia M.A.A. Evers (1,2), Mickael Hilligsmann (1,3), Rana Rizk (4,5)

1 Maastricht University, Faculty of Health Medicine and Life Sciences, Department of Health Services Research, Care and Public Health Research Institute (CAPHRI), Maastricht, The Netherlands.
2 Lebanese University, Faculty of Sciences and Medical Sciences, Hadath, Lebanon.
3 Trimbos Institute, Centre for Economic Evaluations and Machine Learning, Utrecht, The Netherlands.
4 Lebanese American University, School of Arts and Sciences, Department of Natural Sciences, Byblos, Lebanon.
5 Institut National de Santé Publique, d’Épidémiologie Clinique et de Toxicologie, Lebanon (INSPECT-LE)

Introduction
Looking upon Universal Health Coverage, developing Economic Evaluation Guidelines (EEG) to conduct, design, and assess economic evaluation studies is fundamental. Several international organizations as the World Health Organization (WHO), the International Network of Agencies for Health Technology Assessment (INAHHTA), the Guidelines International Network (GIN), and the Appraisal of Guidelines for Research and Evaluation (AGREE) enterprise emphasize the importance of a standardized methodological framework for developing and reporting health system guidance. Lebanon is in need of EEG, which has not been set yet.

Aims
• To develop the Lebanese Economic Evaluation Guideline (LEEG)
• To adopt a transparent, structured, systematic, and standardized methodological framework for developing LEEG
• To provide a tool that can assist international guidelines developers, especially in LMICs, in developing their national ones

Methods

Results
• The guideline development group is composed of one expert in health systems, and representative of potential users, one expert in Health Technology Assessment (HTA) and health economics, and one expert in research synthesis and knowledge translation
• The Lebanese key-stakeholders response rate was 100%
• The Lebanese key-stakeholders survey’s completion rate was 100%
• The Lebanese key-stakeholders were 100% interviewed in-person
• The Lebanese key-stakeholders participation at the consensus workshop was 100%
• The participants involved in the deliberative process were 50% decision-makers
• The deliberative process participants were selected purposively and equitably given their involvement in the Lebanese healthcare system with various backgrounds and expertise in health economics. They were representatives of patients’ advocacy, bioethicists, private payers, public payers, physicians, pharmacists, nurses, academicians, pharmaceutical companies, and the ISPOR Lebanon chapter

References